Author

Filippo Farnia

Institutions: Ospedale Santa Maria della Misericordia di Rovigo, AULSS 5 Polesana

Observed institutions: University of Padua, Azienda Ospedale - Università Padova, Ospedale Santa Maria della Misericordia di Rovigo, AULSS 5 Polesana

ORCID: 0000-0002-0355-467X

Observed ORCID: 0000-0002-0355-467X

OpenAlex ID: A5032221863

Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration

2020 · Gian Paolo Fadini, Mario Luca Morieri, et al. · Diabetes Research and Clinical Practice · 231

RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia

2023 · Teresa Maria Seccia, Tungalagtamir Shagjaa, et al. · Journal of Clinical Medicine · 16

In hospital risk factors for acute kidney injury and its burden in patients with Sars-Cov-2 infection: a longitudinal multinational study

2022 · Mario Luca Morieri, Claudio Ronco, et al. · Scientific Reports · 16

Hyperglycemia, glucocorticoid therapy, and outcome of COVID-19

2020 · Mario Luca Morieri, Gian Paolo Fadini, et al. · Diabetes Research and Clinical Practice · 11

Impact of Bempedoic Acid on Residual Cardiovascular Risk in Hypertensive-dyslipidemic and Diabetic Subjects: a Study Protocol Among Primary Health-care Setting

2025 · Rossella Roversi, Filippo Farnia, et al. · Journal of Hypertension

Works count: 5

Citation count: 274

H-index: 4

I10-index: 4